TY - JOUR

T1 - Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes

T2 - Real-world data from a diabetes out-patient clinic

AU - Hansen, Katrine B.

AU - Svendstrup, Mathilde

AU - Lund, Asger

AU - Knop, Filip K.

AU - Vilsbøll, Tina

AU - Vestergaard, Henrik

N1 - Publisher Copyright: © 2021 Diabetes UK

PY - 2021

Y1 - 2021

N2 - Aims: The once-weekly administered glucagon-like peptide 1 (GLP-1) receptor agonist (GLP-1RA) semaglutide, has, in clinical trials, demonstrated significant reductions in glycated haemoglobin A1c (HbA1c) and body weight in persons with type 2 diabetes. We evaluated the real-world clinical effects of semaglutide once weekly in a hospital-based diabetes out-patient clinic. Methods: This retrospective observational cohort study included persons with type 2 diabetes (n = 119) on a broad range of antidiabetic medicine: GLP-1RA naïve persons (n = 37) and GLP-1RA-experienced persons (n = 82). Person characteristics at inclusion: age [median (quartiles)]: 65 (57, 72) years; body weight 99 (86, 118) kg; body mass index (BMI) 33 (29, 38) kg/m²; HbA1c 61 (54, 69) mmol/mol/(7.7 (7.1, 8.5) %). Data were collected at baseline and after 3, 6 and 12 months of semaglutide treatment. Data were analysed using a general linear mixed model for repeated measurements. Results: After 12 months, the reductions in HbA1c were (mean [95% confidence interval]: GLP-1RA naïve: −12.8 [−17.0, −8.5] mmol/mol/ −1.2 [−1.6, −0.8]% (p < 0.01) and GLP-1RA experienced: −6.4 [−9.0, −3.8] mmol/mol/ −0.6 [−0.8, −0.4]% (p < 0.01), respectively. Body weight reductions in GLP-1RA naïve: −5 [−6.9, −3.1] kg (p < 0.01) and GLP-1RA experienced: −3.2 [−4.4, −2.0] kg (p < 0.01), respectively. Seventy-five percent received 1 mg QW semaglutide. Conclusion: We observed effects of semaglutide once weekly on HbA1c and body weight comparable with the effects observed in clinical studies with fewer persons in our cohort receiving maximum dose of semaglutide.

AB - Aims: The once-weekly administered glucagon-like peptide 1 (GLP-1) receptor agonist (GLP-1RA) semaglutide, has, in clinical trials, demonstrated significant reductions in glycated haemoglobin A1c (HbA1c) and body weight in persons with type 2 diabetes. We evaluated the real-world clinical effects of semaglutide once weekly in a hospital-based diabetes out-patient clinic. Methods: This retrospective observational cohort study included persons with type 2 diabetes (n = 119) on a broad range of antidiabetic medicine: GLP-1RA naïve persons (n = 37) and GLP-1RA-experienced persons (n = 82). Person characteristics at inclusion: age [median (quartiles)]: 65 (57, 72) years; body weight 99 (86, 118) kg; body mass index (BMI) 33 (29, 38) kg/m²; HbA1c 61 (54, 69) mmol/mol/(7.7 (7.1, 8.5) %). Data were collected at baseline and after 3, 6 and 12 months of semaglutide treatment. Data were analysed using a general linear mixed model for repeated measurements. Results: After 12 months, the reductions in HbA1c were (mean [95% confidence interval]: GLP-1RA naïve: −12.8 [−17.0, −8.5] mmol/mol/ −1.2 [−1.6, −0.8]% (p < 0.01) and GLP-1RA experienced: −6.4 [−9.0, −3.8] mmol/mol/ −0.6 [−0.8, −0.4]% (p < 0.01), respectively. Body weight reductions in GLP-1RA naïve: −5 [−6.9, −3.1] kg (p < 0.01) and GLP-1RA experienced: −3.2 [−4.4, −2.0] kg (p < 0.01), respectively. Seventy-five percent received 1 mg QW semaglutide. Conclusion: We observed effects of semaglutide once weekly on HbA1c and body weight comparable with the effects observed in clinical studies with fewer persons in our cohort receiving maximum dose of semaglutide.

KW - GLP-1 receptor agonists

KW - semaglutide once weekly

KW - type 2 diabetes

U2 - 10.1111/dme.14655

DO - 10.1111/dme.14655

M3 - Review

C2 - 34291491

AN - SCOPUS:85111755773

VL - 38

SP - e14655

JO - Diabetic Medicine

JF - Diabetic Medicine

SN - 0742-3071

IS - 10

ER -